Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017

- Conference Call and Webcast to Follow at 8:00 a.m. ET/ 5:00 a.m. PT -

BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for the fourth quarter and full year 2016 will be released on Wednesday, March 15, 2017, before U.S. markets open. At 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time, Aimmune management will host a conference call to discuss its financial results and provide a general business update.

The conference call will be accessible via the company’s website at on the Events page under Investor Relations. Please connect to the company’s website at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-877-497-1438 (U.S.) or 1-262-558-6296 (international) and provide the conference ID # 84650109 to join by phone.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see

Source: Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D., 650-396-3814
Stephanie Yao, 650-351-6479